Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Superficial bladder cancer. A 10 year experience

H B Tongaonkar1, A V Dalal, J N Kulkarni

  • 1Tata Memorial Hospital, Dr. E. Borges Marg, Parel, Bombay, India.

Indian Journal of Cancer
|September 1, 1995
PubMed
Summary

Superficial bladder cancer patients treated with transurethral resection showed varying survival rates based on tumor grade and number. Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy significantly lowered stage progression compared to chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma.

South Asian journal of cancer·2016
Same author

Outcome of radical prostatectomy as primary treatment for high-risk prostate cancer patients.

Indian journal of cancer·2016
Same author

Leiomyosarcoma of penis.

Indian journal of cancer·2016
Same author

A rare case of recurrent intravenous leiomyomatosis: Role of GnRH analogues?

Indian journal of cancer·2016
Same author

Uterine smooth muscle tumors of uncertain malignant potential and atypical leiomyoma: a morphological study of these grey zones with clinical correlation.

Indian journal of pathology & microbiology·2012
Same author

CDX2 positivity in metastatic endometrial carcinoma to the lung: a diagnostic pitfall.

Indian journal of pathology & microbiology·2012

Area of Science:

  • Urology
  • Oncology
  • Cancer Research

Background:

  • Superficial bladder cancer (stage TaT1) management involves transurethral resection.
  • Adjuvant intravesical therapies are used for high-risk patients to prevent recurrence and progression.

Purpose of the Study:

  • To evaluate the survival outcomes and recurrence patterns in superficial bladder cancer patients treated with transurethral resection.
  • To assess the efficacy of intravesical chemotherapy and immunotherapy in reducing recurrence and stage progression.

Main Methods:

  • Retrospective analysis of 236 patients with superficial bladder cancer (stage TaT1) treated with transurethral resection.
  • Comparison of survival rates based on tumor number (single vs. multiple) and grade (I, II, III).
  • Evaluation of intravesical thiotepa, mitomycin, and Bacillus Calmette-Guérin (BCG) response rates and impact on recurrence and progression.

Related Experiment Videos

Main Results:

  • Tumor grade significantly impacted survival rates, independent of tumor number.
  • Intravesical Bacillus Calmette-Guérin (BCG) demonstrated higher response rates (71.5%) compared to thiotepa (54.9%) and mitomycin (60%).
  • All intravesical agents reduced local recurrence rates, but only BCG significantly lowered stage progression rates.

Conclusions:

  • Tumor grade is a critical prognostic factor in superficial bladder cancer.
  • Intravesical BCG is effective in reducing both recurrence and stage progression, showing comparable efficacy to other strains.
  • Adjuvant intravesical therapies, particularly BCG, play a vital role in managing high-risk superficial bladder cancer.